Format

Send to

Choose Destination
J Crohns Colitis. 2016 Oct;10(10):1179-85. doi: 10.1093/ecco-jcc/jjw129. Epub 2016 Jul 11.

Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.

Author information

1
Departement of Hepato-Gastroenterology, Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France.
2
Department of Hepato-Gastroenterology, Hôpital Haut-Lévêque, Pessac, France.
3
Department of Hepato-Gastroenterology, Hôpital Saint Antoine, Paris, France.
4
Department of Hepato-Gastroenterology, Hôpital Saint Louis, France.
5
Department of Hepato-Gastroenterology Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France.
6
Department of Hepato-Gastroenterology, Hôpital Mondor, Créteil, France.
7
Department of Hepato-Gastroenterology, Centre Hospitalier Universitaire de Tours, Tours, France.
8
Department of Hepato-Gastroenterology, Hôpital Nord, Amiens, France.
9
Department of Hepato-Gastroenterology, Hôpital Saint-Eloi, Montpellier, France.
10
Department of Hepato-Gastroenterology, Hôpital La Source-Beaulieu, Lausanne, Suisse.
11
Department of Hepato-Gastroenterology, Hôpital Saint-Joseph, Paris, France.
12
Department of Hepato-Gastroenterology, Centre Hospitalier Universitaire de Nantes, Nantes, France.
13
Department of Hepato-Gastroenterology, Hôpital Pontchaillou, Rennes, France.
14
Department of Hepato-Gastroenterology, Hôpital Beaujon, Clichy, France.
15
Department of Hepato-Gastroenterology, Hôpital Hôtel Dieu, Clermont Ferrand, France.
16
Department of Hepato-Gastroenterology, Centre Hospitalier Universitaire d'Angers, Angers, France.
17
Department of Hepato-Gastroenterology, Hôpital de Brabois, Nancy, France.
18
Department of Hepato-Gastroenterology, Hôpital Côte de Nacre, Caen, France.
19
Department of Hepato-Gastroenterology, Hôpital de l'Archet, Nice, France.
20
Department of Hepato-Gastroenterology, Hôpital Cochin, Paris, France.
21
Departement of Hepato-Gastroenterology, Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France snahon@ch-montfermeil.fr snahon@club-internet.fr.

Abstract

AIM:

to describe the characteristics of incident cases of tuberculosis [TB] despite negative TB screening tests, in patients with inflammatory bowel disease [IBD] undergoing anti-TNF treatment, and to identify the risk factors involved.

METHODS:

A retrospective descriptive study was conducted at GETAID centers on all IBD patients undergoing anti-TNF treatment who developed TB even though their initial screening test results were negative. The following data were collected using a standardized anonymous questionnaire: IBD, and TB characteristics and evolution, initial screening methods and results, and time before anti-TNF treatment was restarted.

RESULTS:

A total of 44 IBD patients [including 23 men; median age 37 years] were identified at 20 French and Swiss centers at which TB screening was performed [before starting anti-TNF treatment] based on Tuberculin Skin Tests [n = 25], Interferon Gamma Release Assays [n = 12], or both [n = 7]. The median interval from the start of anti-TNF treatment to TB diagnosis was 14.5 months (interquartile range [IQR] 25-75: 4.9-43.3). Pulmonary TB involvement was observed in 25 [57%] patients, and 40 [91%] had at least one extrapulmonary location. One TB patient died as the result of cardiac tamponade. Mycobacterium tuberculosis exposure was thought to be a possible cause of TB in 14 cases [32%]: 7 patients [including 6 health care workers] were exposed to occupational risks, and 7 had travelled to endemic countries. Biotherapy was restarted on 27 patients after a median period of 11.2 months [IQR 25-75: 4.4-15.2] after TB diagnosis without any recurrence of the infection.

CONCLUSION:

Tuberculosis can occur in IBD patients undergoing anti-TNF treatment, even if their initial screening results were negative. In the present population, TB was mostly extrapulmonary and disseminated. TB screening tests should be repeated on people exposed to occupational risks and/or travelers to endemic countries. Restarting anti-TNF treatment seems to be safe.

KEYWORDS:

Crohn’s disease; Inflammatory bowel disease; anti-TNF; screening; tuberculosis; ulcerative colitis

PMID:
27402916
DOI:
10.1093/ecco-jcc/jjw129
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center